Stammers D K, Dann J G, Harris C J, Smith D R
Wellcome Research Laboratories, Beckenham, Kent, United Kingdom.
Arch Biochem Biophys. 1987 Nov 1;258(2):413-20. doi: 10.1016/0003-9861(87)90362-6.
The kinetic properties of two different substrates for human renin, a synthetic tetradecapeptide and the natural substrate human angiotensinogen, have been compared. While the Vmax was similar for the two substrates, the Km values differed by a factor of 10, i.e., 11.7 +/- 0.7 microM (tetradecapeptide) and 1.0 +/- 0.1 microM (angiotensinogen). The mode of inhibition of renin by a statine (Sta)-containing hexapeptide, BW897C, that is a close structural analog of residues 8-13 of human angiotensinogen (Phe-His-Sta-Val-Ile-His-OMe), was determined for the two substrates. Competitive inhibition was observed when tetradecapeptide was the substrate (Ki = 2.0 +/- 0.2 microM), but a more complex mixed inhibition mode (Ki = 1.7 +/- 0.1 microM, Ki' = 3.0 +/- 0.23 microM) was found with angiotensinogen as substrate. This mixed inhibition probably results from the formation of an enzyme-inhibitor-substrate or enzyme-inhibitor-product complex and reflects the more extensive interactions that the protein angiotensinogen, as opposed to the small tetradecapeptide substrate, can make with renin. We conclude that the mixed inhibition observed when angiotensinogen is used as renin substrate could be important in the clinical application of renin inhibitors because it is less readily reversed by increased concentrations of substrate than is simple competitive inhibition.
已对人肾素的两种不同底物——一种合成十四肽和天然底物人血管紧张素原的动力学特性进行了比较。虽然两种底物的Vmax相似,但Km值相差10倍,即11.7±0.7微摩尔(十四肽)和1.0±0.1微摩尔(血管紧张素原)。测定了一种含statine(Sta)的六肽BW897C对肾素的抑制模式,该六肽是与人类血管紧张素原8-13位残基(苯丙氨酸-组氨酸-Sta-缬氨酸-异亮氨酸-组氨酸-甲氧基)结构相近的类似物,底物分别为上述两种。当以十四肽为底物时观察到竞争性抑制(Ki = 2.0±0.2微摩尔),但以血管紧张素原为底物时发现了更复杂的混合抑制模式(Ki = 1.7±0.1微摩尔,Ki' = 3.0±0.23微摩尔)。这种混合抑制可能是由于形成了酶-抑制剂-底物或酶-抑制剂-产物复合物,反映了与小的十四肽底物相比,蛋白质血管紧张素原与肾素之间能发生更广泛的相互作用。我们得出结论,当以血管紧张素原为肾素底物时观察到的混合抑制在肾素抑制剂的临床应用中可能很重要,因为与简单的竞争性抑制相比,增加底物浓度时它不太容易被逆转。